| Date | Title | Description |
| 08.04.2026 | We’re exiting our position in a drug stock and initiating a stake in a more attractive rival | - |
| 16.03.2026 | This biotech stock is up more than 1,000% since late July. Jefferies thinks there are more gains ahead | - |
| 15.01.2026 | This pharma stock just got whacked — there’s still a major catalyst ahead | - |
| 27.02.2025 | Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025
Investigational New Drug (IND) applications in two additional indications have received FDA clearan... |
| 29.06.2024 | ALT Deadline: ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit | NEW YORK, June 29, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between Decem... |
| 21.06.2024 | ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit | NEW YORK, June 21, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "C... |
| 13.06.2024 | ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit | NEW YORK, June 13, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "C... |
| 29.05.2024 | ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT | NEW YORK, May 29, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Cl... |
| 22.05.2024 | ROSEN, SKILLED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT | NEW YORK, May 22, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Cl... |
| 15.05.2024 | ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT | NEW YORK, May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Cl... |
| 08.05.2024 | ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALT | NEW YORK, May 8, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and... |
| 29.03.2024 | A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug | Health A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
Hilary Brueck
2024-03-29T16:38:44Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email... |
| 30.11.2023 | Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide | Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment
Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks
Robust reductions in BMI and s... |
| 20.12.2022 | Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) | Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeks
Significant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver i... |
| 28.09.2021 | French biotech and Pfizer find positives in data for Lyme disease vaccine candidate; Altimmune's obesity drug shows promise in PhI trial | French biotech Valneva and partner Pfizer continued to reveal positive results from its Phase II trial for its Lyme disease vaccine candidate.
The Phase II study, which enrolled 246 healthy adults between 18-65 in the US, ... |
| 15.03.2021 | AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection | New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University
Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication
Systemic and Mucosal Antibody... |
| 12.03.2021 | Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza | GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing coll... |
| 08.03.2021 | Altimmune to Present at Upcoming Conferences | GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright ... |
| 25.02.2021 | Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate | Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers
Intranasal administration targets the virus at its point of entry and in a preclinical study induced local nasa... |
| 25.02.2021 | Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update | Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced
Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun
ALT-801 is Progressing Through the Phase 1 Clinical Trial
Solidly Capitalized to Ad... |
| 22.07.2020 | Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19 | GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vigene Biosciences (“Vigene”) to manufacture... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 21.08.2019 | Altimmune Announces $3.7M In Additional BARDA Funding | GAITHERSBURG, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existin... |
| 12.03.2019 | Altimmune Closes $14M Registered Direct Offering | GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-fun... |
| 12.03.2019 | Altimmune Closes $14M Registered Direct Offering | GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-fun... |
| 08.10.2018 | Altimmune Closes on $16.9M in Funding | Altimmune, Inc. (Nasdaq: ALT), a Gaithersburg, MD-based clinical-stage immunotherapeutics company, closed the previously announced underwritten public offering of common units and pre-funded units for gross proceeds of $12m.
Together with t... |
| 03.10.2018 | Altimmune Closes on $16.9 Million in Funding | GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it closed the previously announced underwritten public offering of common units and pre-funded ... |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companies | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ... |
| 17.08.2017 | Altimmune Announces $14.7 Million Series B | GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors t... |
| - | PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases | FOR IMMEDIATE RELEASE
Contact for Altimmune, Inc.
Bill Enright Investor Relations
President and Chief Executive Officer
240-654-1450
*protected email*
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics
Company Tar... |
| - | Altimmune Announces $4.9 million Registered Direct Offering of Common Stock | GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional investors for the purchase i... |
| - | Altimmune Announces Positive Results from NasoVAX Extension Study | Seroprotective HAI antibody response persisted more than one year after vaccination
Company seeking partnership for further development and commercialization of NasoVAX
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. ... |
| - | Altimmune to Present at the 28th Annual Piper Jaffray Healthcare Conference | GAITHERSBURG, Md., Nov. 18, 2016 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 28th Annual Piper Jaffray Healthcare Conference to be held November 2... |
| - | Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion | GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline.
NasoVAX
As previous... |
| - | Altimmune Expands Clinical Development Team | Appoints Sybil Tasker as Senior Vice President, Clinical Research and Development
Names Efe Egharevba as Head of Clinical Project Management
GAITHERSBURG, MD., April 5, 2016 — Altimmune, Inc., a clinical stage immunotherapeutic company, t... |
| - | Altimmune Announces $25 million Registered Direct Offering | GAITHERSBURG, Md., Oct. 08, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with several institutional investors for the purchase o... |
| - | Altimmune to Announce Second Quarter 2018 Financial Results on August 15 | GAITHERSBURG, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the three and six months ended June 30, 2018 before ... |
| - | Altimmune Announces Pricing of $12 Million Underwritten Public Offering | GAITHERSBURG, Md., Sept. 28, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of common units and pre-funded units for a combi... |
| - | Altimmune Restructures Financing Agreement | GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into an agreement with the lead investor... |
| - | Altimmune Announces $14.7 Million Series B Preferred Stock Offering | GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors to... |
| - | Altimmune to Present at the BIO CEO & Investor Conference | GAITHERSBURG, Md., Feb. 6, 2017 /PRNewswire/ — Altimmune, Inc., a clinical stage immunotherapeutics company targeting infectious diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO & Investor ... |
| - | Altimmune Announces Presentation at Biotech Showcase 2016 | Gaithersburg, Maryland – DEC. 21, 2015 – Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11– 13, 2016 in San Francisco, CA.
Bill En... |
| - | Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™ | GAITHERSBURG, Md., March 28, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeutics company, today announced that the Company was awarded a contract modification to their previously announced contract. Under the U.S. B... |
| - | Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer | GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sy... |
| - | Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update | Conference call and webcast scheduled for Tuesday, April 2, at 8:30 am Eastern Time
GAITHERSBURG, Md., April 01, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial ... |
| - | Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. | Dr. Sybil Tasker to present on April 16 at 12:55pm Eastern Time
GAITHERSBURG, Md., April 11, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the Wo... |
| - | Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016 | GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in He... |
| - | Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases | GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed ... |
| - | Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET
GAITHERSBURG, Md., May 15, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the... |
| - | Altimmune Closes on $16.9 Million in Funding | $12 million underwritten public offering closed October 2
$4.9 million registered direct offering closed September 26
GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics c... |
| - | Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria | GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12,... |
| - | Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update | Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time
GAITHERSBURG, Md., Aug. 13, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financia... |
| - | Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development | New funding will allow examination of mucosal immune response and additional vaccine characterization
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today an... |
| - | Altimmune to Announce Second Quarter 2019 Financial Results on August 14 | GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial ... |
| - | Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B... | NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprotection
HepTcell vaccine was well tolerated but T-cell immunogenicity results were inconclusive
GAITHERSBURG, Md., March 27, 2018 (GLOBE NEW... |
| - | Altimmune to Announce Year End 2017 Financial Results on March 29 | GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before ... |
| - | Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs | GAITHERSBURG, Md., June 05, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United ... |
